Experienced in Virilizing Ovarian Tumor

Dr. Stephen K. Williamson

Oncology
2330 Shawnee Mission Pkwy, 
Westwood, KS 
 (1197.0 mi)
Accepting New Patients
Experienced in Virilizing Ovarian Tumor
2330 Shawnee Mission Pkwy, 
Westwood, KS 
 (1197.0 mi)
OverviewInsuranceLocationsClinical Research

Overview

Stephen Williamson is an Oncologist in Westwood, Kansas. Dr. Williamson and is rated as an Experienced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Adult Soft Tissue Sarcoma, Endoscopy, and Bone Marrow Aspiration. Dr. Williamson is currently accepting new patients.

His clinical research consists of co-authoring 38 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in KS
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Oscar
  •  Humana

Locations

2330 Shawnee Mission Pkwy, Westwood, KS 66205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2024
Intervention Type: Other, Drug
Study Drugs: Topotecan Hydrochloride, Veliparib
Study Phase: Phase 1/Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Multi-center, Open-label, Single-arm, Dose-escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase 1, Multi-center, Open-label, Single-arm, Dose-escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: FN-1501
Study Phase: Phase 1
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Enrollment Status: Unknown
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma
A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma
Enrollment Status: Completed
Publish Date: March 24, 2021
Intervention Type: Biological
Study Phase: Phase 2
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

38 Total Publications

First-In-Human Dose-Escalation Study of Fianlimab, an Anti-Lymphocyte Activation Gene-3 Antibody, with Cemiplimab in patients with advanced malignancies.
First-In-Human Dose-Escalation Study of Fianlimab, an Anti-Lymphocyte Activation Gene-3 Antibody, with Cemiplimab in patients with advanced malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 02, 2024
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Robert E. Pluenneke
Hematology Oncology | Hematology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Robert E. Pluenneke
Hematology Oncology | Hematology | Oncology

University Of Kansas Hospital Authority

2800 Clay Edwards Dr, N Ks City Hosp, 
Kansas City, MO 
 (8.7 mi)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Pluenneke is a Hematologist Oncology specialist and a Hematologist in Kansas City, Missouri. Dr. Pluenneke and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, Bone Marrow Aspiration, and Ureteroscopy. Dr. Pluenneke is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Andrea D. Jewell
Obstetrics and Gynecology | Gynecologic Oncology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Andrea D. Jewell
Obstetrics and Gynecology | Gynecologic Oncology | Oncology

Kansas University Physicians Inc

3901 Rainbow Blvd, 
Kansas City, KS 
 (1.7 mi)
913-588-3315
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrea Jewell is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Kansas City, Kansas. Dr. Jewell and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Salpingo-Oophorectomy, and Intrauterine Device Insertion. Dr. Jewell is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Jason A. Knight
Gynecologic Oncology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Jason A. Knight
Gynecologic Oncology | Oncology

Saint Lukes Physician Group Inc

4321 Washington St, Suite 4000, 
Kansas City, MO 
 (1.5 mi)
816-932-3300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Knight is a Gynecologic Oncologist and an Oncologist in Kansas City, Missouri. Dr. Knight and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Hysterectomy, and Oophorectomy. Dr. Knight is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile